Systematic Reviews
Copyright ©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. May 6, 2016; 7(2): 294-305
Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.294
Figure 5
Figure 5 Manufacturer and user device experience databank. A: Reports about adverse events related to therapy with Interstim are plotted as a function of month of posting by the Federal Drug Administration; B: The lower panel depicts the percentage of reports mentioning gastrointestinal problems (squares) or specifically fecal incontinence (circles) as indication for sacral neurostimulation.